186 related articles for article (PubMed ID: 31445162)
1. Preclinical development of a high affinity α-synuclein antibody, MEDI1341, that can enter the brain, sequester extracellular α-synuclein and attenuate α-synuclein spreading in vivo.
Schofield DJ; Irving L; Calo L; Bogstedt A; Rees G; Nuccitelli A; Narwal R; Petrone M; Roberts J; Brown L; Cusdin F; Dosanjh B; Lloyd C; Dobson C; Gurrell I; Fraser G; McFarlane M; Rockenstein E; Spencer B; Masliah E; Spillantini MG; Tan K; Billinton A; Vaughan T; Chessell I; Perkinton MS
Neurobiol Dis; 2019 Dec; 132():104582. PubMed ID: 31445162
[TBL] [Abstract][Full Text] [Related]
2. Development of an aggregate-selective, human-derived α-synuclein antibody BIIB054 that ameliorates disease phenotypes in Parkinson's disease models.
Weihofen A; Liu Y; Arndt JW; Huy C; Quan C; Smith BA; Baeriswyl JL; Cavegn N; Senn L; Su L; Marsh G; Auluck PK; Montrasio F; Nitsch RM; Hirst WD; Cedarbaum JM; Pepinsky RB; Grimm J; Weinreb PH
Neurobiol Dis; 2019 Apr; 124():276-288. PubMed ID: 30381260
[TBL] [Abstract][Full Text] [Related]
3. Novel naturally occurring autoantibodies attenuate α-synuclein pathology in a mouse model of Parkinson's disease.
Li Y; Wang T; Meng L; Jin L; Liu C; Liang Y; Ren L; Liu Y; Liu Y; Liu S; Li T; Liang Y; Chen X; Zhang Z
Neuropathol Appl Neurobiol; 2023 Feb; 49(1):e12860. PubMed ID: 36331758
[TBL] [Abstract][Full Text] [Related]
4. Iron reduces the propagation of pathological α-synuclein: An Editorial Highlight for "Brain iron enrichment attenuates α-synuclein spreading after injection of preformed fibrils" on page 554.
Guo YJ; Ayton S; Lei P
J Neurochem; 2021 Nov; 159(3):414-416. PubMed ID: 34296424
[TBL] [Abstract][Full Text] [Related]
5. NK cells clear α-synuclein and the depletion of NK cells exacerbates synuclein pathology in a mouse model of α-synucleinopathy.
Earls RH; Menees KB; Chung J; Gutekunst CA; Lee HJ; Hazim MG; Rada B; Wood LB; Lee JK
Proc Natl Acad Sci U S A; 2020 Jan; 117(3):1762-1771. PubMed ID: 31900358
[TBL] [Abstract][Full Text] [Related]
6. Extracellular clusterin limits the uptake of α-synuclein fibrils by murine and human astrocytes.
Filippini A; Mutti V; Faustini G; Longhena F; Ramazzina I; Rizzi F; Kaganovich A; Roosen DA; Landeck N; Duffy M; Tessari I; Bono F; Fiorentini C; Greggio E; Bubacco L; Bellucci A; Missale M; Cookson MR; Gennarelli M; Russo I
Glia; 2021 Mar; 69(3):681-696. PubMed ID: 33045109
[TBL] [Abstract][Full Text] [Related]
7. Clearing Extracellular Alpha-Synuclein from Cerebrospinal Fluid: A New Therapeutic Strategy in Parkinson's Disease.
Menéndez-González M; Padilla-Zambrano HS; Tomás-Zapico C; García BF
Brain Sci; 2018 Mar; 8(4):. PubMed ID: 29570693
[TBL] [Abstract][Full Text] [Related]
8. Propagation of pathological α-synuclein in marmoset brain.
Shimozawa A; Ono M; Takahara D; Tarutani A; Imura S; Masuda-Suzukake M; Higuchi M; Yanai K; Hisanaga SI; Hasegawa M
Acta Neuropathol Commun; 2017 Feb; 5(1):12. PubMed ID: 28148299
[TBL] [Abstract][Full Text] [Related]
9. 14-3-3 Proteins Reduce Cell-to-Cell Transfer and Propagation of Pathogenic α-Synuclein.
Wang B; Underwood R; Kamath A; Britain C; McFerrin MB; McLean PJ; Volpicelli-Daley LA; Whitaker RH; Placzek WJ; Becker K; Ma J; Yacoubian TA
J Neurosci; 2018 Sep; 38(38):8211-8232. PubMed ID: 30093536
[TBL] [Abstract][Full Text] [Related]
10. Α-synuclein immunotherapy blocks uptake and templated propagation of misfolded α-synuclein and neurodegeneration.
Tran HT; Chung CH; Iba M; Zhang B; Trojanowski JQ; Luk KC; Lee VM
Cell Rep; 2014 Jun; 7(6):2054-65. PubMed ID: 24931606
[TBL] [Abstract][Full Text] [Related]
11. Reducing C-terminal-truncated alpha-synuclein by immunotherapy attenuates neurodegeneration and propagation in Parkinson's disease-like models.
Games D; Valera E; Spencer B; Rockenstein E; Mante M; Adame A; Patrick C; Ubhi K; Nuber S; Sacayon P; Zago W; Seubert P; Barbour R; Schenk D; Masliah E
J Neurosci; 2014 Jul; 34(28):9441-54. PubMed ID: 25009275
[TBL] [Abstract][Full Text] [Related]
12. ABBV-0805, a novel antibody selective for soluble aggregated α-synuclein, prolongs lifespan and prevents buildup of α-synuclein pathology in mouse models of Parkinson's disease.
Nordström E; Eriksson F; Sigvardson J; Johannesson M; Kasrayan A; Jones-Kostalla M; Appelkvist P; Söderberg L; Nygren P; Blom M; Rachalski A; Nordenankar K; Zachrisson O; Amandius E; Osswald G; Moge M; Ingelsson M; Bergström J; Lannfelt L; Möller C; Giorgetti M; Fälting J
Neurobiol Dis; 2021 Dec; 161():105543. PubMed ID: 34737044
[TBL] [Abstract][Full Text] [Related]
13. Pharmacological inhibition and knockdown of O-GlcNAcase reduces cellular internalization of α-synuclein preformed fibrils.
Tavassoly O; Yue J; Vocadlo DJ
FEBS J; 2021 Jan; 288(2):452-470. PubMed ID: 32365408
[TBL] [Abstract][Full Text] [Related]
14. Naturally occurring antibodies isolated from PD patients inhibit synuclein seeding in vitro and recognize Lewy pathology.
Li X; Koudstaal W; Fletcher L; Costa M; van Winsen M; Siregar B; Inganäs H; Kim J; Keogh E; Macedo J; Holland T; Perry S; Bard F; Hoozemans JJ; Goudsmit J; Apetri A; Pascual G
Acta Neuropathol; 2019 May; 137(5):825-836. PubMed ID: 30805666
[TBL] [Abstract][Full Text] [Related]
15. Antibodies against alpha-synuclein: tools and therapies.
Vaikath NN; Hmila I; Gupta V; Erskine D; Ingelsson M; El-Agnaf OMA
J Neurochem; 2019 Sep; 150(5):612-625. PubMed ID: 31055836
[TBL] [Abstract][Full Text] [Related]
16. Anti-α-synuclein c-terminal antibodies block PFF uptake and accumulation of phospho-synuclein in preclinical models of Parkinson's disease.
Brendza R; Gao X; Stark KL; Lin H; Lee SH; Hu C; Cai H; DiCara D; Hsiao YC; Ngu H; Foreman O; Baca M; Dohse M; Fortin JP; Corpuz R; Seshasayee D; Easton A; Ayalon G; Hötzel I; Chih B
Neurobiol Dis; 2023 Feb; 177():105969. PubMed ID: 36535551
[TBL] [Abstract][Full Text] [Related]
17. Generation and characterization of novel conformation-specific monoclonal antibodies for α-synuclein pathology.
Vaikath NN; Majbour NK; Paleologou KE; Ardah MT; van Dam E; van de Berg WD; Forrest SL; Parkkinen L; Gai WP; Hattori N; Takanashi M; Lee SJ; Mann DM; Imai Y; Halliday GM; Li JY; El-Agnaf OM
Neurobiol Dis; 2015 Jul; 79():81-99. PubMed ID: 25937088
[TBL] [Abstract][Full Text] [Related]
18. Endogenous Levels of Alpha-Synuclein Modulate Seeding and Aggregation in Cultured Cells.
Vasili E; Dominguez-Meijide A; Flores-León M; Al-Azzani M; Kanellidi A; Melki R; Stefanis L; Outeiro TF
Mol Neurobiol; 2022 Feb; 59(2):1273-1284. PubMed ID: 34984585
[TBL] [Abstract][Full Text] [Related]
19. Characterization of novel conformation-selective α-synuclein antibodies as potential immunotherapeutic agents for Parkinson's disease.
Henderson MX; Covell DJ; Chung CH; Pitkin RM; Sandler RM; Decker SC; Riddle DM; Zhang B; Gathagan RJ; James MJ; Trojanowski JQ; Brunden KR; Lee VMY; Luk KC
Neurobiol Dis; 2020 Mar; 136():104712. PubMed ID: 31837422
[TBL] [Abstract][Full Text] [Related]
20. Stereotaxic Targeting of Alpha-Synuclein Pathology in Mouse Brain Using Preformed Fibrils.
Zhang B; Kehm V; Gathagan R; Leight SN; Trojanowski JQ; Lee VM; Luk KC
Methods Mol Biol; 2019; 1948():45-57. PubMed ID: 30771169
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
